A new study led by Neurocode Labs evaluated two pTau217 assays for Alzheimer's Diagnosis.
One of the goals of the study was to improve patient care and early diagnosis. The two assays studied were Neurocode's ALZpath pTau217 blood test and the Fujirebio assay.
Researchers examined 170 plasma samples using the pTau217 assays. “Decision points were determined using CSF testing and autopsy findings as the standard,” according to the published study. Both tests “showed equal performance based on CSF testing.”
According to a Neurocode Labs release, their “ALZpath pTau217 blood test is as accurate as brain imaging or CSF testing for diagnosing Alzheimer's.” They are the only U.S. laboratory to provide this assay as a “laboratory developed test (LDT) for clinical use.” The facility is CAP-accredited and CLIA-certified.
The ALZpath test excelled in early Alzheimer's Diagnosis, according to the Neurocode.
The study is published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
